COVID-19 Overview, Case Definition, Clinical Features & Disease Course

Introduction

Coronavirus Disease 2019 (COVID-19) is an acute infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a novel coronavirus belonging to the family Coronaviridae and the order Nidovirales. SARS-CoV-2 is genetically related to the viruses responsible for Severe Acute Respiratory Syndrome (SARS) in 2003 and Middle East Respiratory Syndrome (MERS).

The virus is believed to have originated from an animal (zoonotic) source, followed by sustained human-to-human transmission. COVID-19 was first identified in Wuhan, Hubei Province, China, in December 2019, and on 11 March 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic due to its rapid worldwide spread.

The incubation period generally ranges from 1 to 14 days, with a median of approximately 5 days, although symptoms may develop earlier or later depending on individual factors.

Purpose of this Guideline

This guideline provides a comprehensive evidence-based clinical care pathway for patients with COVID-19, covering the entire continuum of care from screening and diagnosis through treatment, monitoring, rehabilitation, and discharge.

Special consideration is given to vulnerable populations, including:

• Pediatric patients

• Older adults

• Pregnant women

• Immunocompromised individuals

• Patients with chronic medical conditions

The guideline promotes a multidisciplinary approach involving physicians, nurses, laboratory personnel, pharmacists, physiotherapists, mental health professionals, nutritionists, infection prevention teams, and public health personnel.

COVID-19 Care Pathway

Following presentation to a healthcare facility, every patient should undergo systematic assessment.

Step 1: Screening

Patients are screened for symptoms, epidemiological risk factors, and exposure history.

↓

Step 2: Case Classification

Patients are classified as:

• Suspect case

• Probable case

• Confirmed case

↓

Step 3: Clinical Assessment

Disease severity is determined using clinical examination, laboratory investigations, imaging, and oxygenation assessment.

↓

Step 4: Treatment and Monitoring

Patients receive appropriate isolation, supportive care, pharmacologic treatment where indicated, and continuous monitoring.

↓

Step 5: Outcome

Patients leave the COVID-19 care pathway through:

• Recovery and discharge

• Referral or transfer

• Death certification (where applicable)

Patients who do not meet COVID-19 case criteria should continue through the routine non-COVID clinical pathway.

Primary Objectives

The primary objectives of COVID-19 management are to:

• Provide safe, timely, and high-quality patient care

• Confirm diagnosis and classify disease severity accurately

• Prevent onward transmission within healthcare facilities and the community

• Reduce complications, disability, and mortality

• Provide comprehensive psychosocial support

• Promote early rehabilitation and recovery

Psychosocial Support

Psychological and social support should be integrated into routine COVID-19 care.

Support should be offered to:

• Patients with confirmed or suspected COVID-19

• Family members

• Caregivers

• Bereaved relatives

• Individuals recovering from COVID-19

Core psychosocial interventions include:

• Clear communication and reassurance

• Anxiety and fear reduction

• Emotional support during isolation

• Grief counselling

• Addressing stigma and discrimination

• Reintegration support after recovery

Evidence-based practice

COVID-19 management continues to evolve as new scientific evidence emerges. Recommendations should therefore:

• Be updated regularly

• Follow current national and international guidelines

• Be based on high-quality clinical evidence

• Address prevention, diagnosis, treatment, rehabilitation, and long-term follow-up

Epidemiology and modes of transmission

Current evidence indicates that SARS-CoV-2 spreads primarily through respiratory secretions and close person-to-person contact.

Transmission occurs through:

• Inhalation of respiratory droplets and aerosols produced during coughing, sneezing, talking, singing, or breathing

• Direct close contact with an infected individual

• Indirect transmission through contaminated hands after touching contaminated surfaces (fomites), followed by touching the eyes, nose, or mouth

Individuals infected with SARS-CoV-2 may contaminate frequently touched objects such as:

• Door handles

• Tables

• Handrails

• Medical equipment

• Mobile phones

• Shared surfaces

Although fomite transmission is less common than airborne or droplet transmission, strict hand hygiene and environmental cleaning remain essential components of infection prevention.

Transmission may occur from:

• Symptomatic individuals

• Pre-symptomatic individuals

• Asymptomatic individuals

This contributes substantially to community spread.

Case definitions

Case definitions may be revised as new epidemiological evidence becomes available.

Suspect case

A patient with acute respiratory illness (fever and at least one respiratory symptom such as cough or shortness of breath) and a history of travel to or residence in an area with community transmission during the 14 days before symptom onset.

OR

A patient with any acute respiratory illness who has had contact with a confirmed or probable COVID-19 case within the previous 14 days.

OR

A patient with severe acute respiratory illness (SARI) requiring hospitalization, with no alternative diagnosis that fully explains the clinical presentation.

Probable case

A suspect case in whom:

• COVID-19 laboratory testing is inconclusive,

OR

• A pan-coronavirus assay is positive without identification of another respiratory pathogen,

OR

• Testing cannot be performed for any reason,

OR

• There is an epidemiological link to confirmed cases or an outbreak,

OR

• Chest CT or chest radiography demonstrates imaging findings highly suggestive of COVID-19.

Confirmed case

A person with laboratory-confirmed SARS-CoV-2 infection by:

• Real-time Reverse Transcriptase Polymerase Chain Reaction (rRT-PCR) or another validated NAAT,

OR

A suspect case with a strong epidemiological link and positive SARS-CoV-2 antigen testing using validated assays,

OR

Where nationally recommended, a suspect case with strong epidemiological linkage and validated serological evidence of recent SARS-CoV-2 infection.

Clinical features

COVID-19 presents with a broad spectrum of illness ranging from asymptomatic infection to life-threatening multi-organ failure.

Most common symptoms

• Fever

• Dry cough

• Fatigue

• Malaise

Other common symptoms

• Headache

• Sore throat

• Loss of smell (anosmia)

• Loss of taste (ageusia)

• Runny nose

• Nasal congestion

• Chills

• Muscle aches (myalgia)

• Back pain

• Chest discomfort

• Diarrhea

• Nausea

• Vomiting

• Conjunctivitis

• Skin rash

• Discoloration of fingers or toes

Severe symptoms (Severe acute respiratory infection)

Patients with severe disease may develop:

• Difficulty breathing

• Shortness of breath

• Persistent chest pain or pressure

• Hypoxia

• Cyanosis

• Confusion

• Loss of speech

• Reduced consciousness

• Loss of movement

These symptoms require urgent medical evaluation.

High-risk groups for severe disease

Patients at increased risk of severe illness include:

• Older adults

• Serious cardiovascular disease (heart failure, coronary artery disease, cardiomyopathy)

• Chronic obstructive pulmonary disease (COPD)

• Moderate-to-severe asthma

• Diabetes mellitus (Type 1 or Type 2)

• Chronic kidney disease

• Chronic liver disease

• Severe obesity

• Cancer

• Cystic fibrosis

• Sickle cell disease

• Immunocompromised patients, including those:

  • Receiving chemotherapy

  • Receiving immunosuppressive medications

  • Living with advanced HIV infection

  • Following solid organ transplantation

  • Following bone marrow transplantation

• Pregnant women with significant comorbidities

Disease Pathophysiology and clinical course

COVID-19 is a dynamic disease characterized by viral replication followed by host immune activation, pulmonary injury, and—in some patients—a dysregulated systemic inflammatory response.

Phase I — Early viral replication Phase

Timeframe: Day 0–5

Pathophysiology

• Virus enters through the respiratory mucosa

• SARS-CoV-2 binds to ACE2 receptors on respiratory epithelial cells

• Rapid viral replication occurs in the upper respiratory tract

• Minimal inflammatory response

• Peak viral shedding occurs during this phase

Clinical features

• Asymptomatic infection

• Mild fatigue

• Mild sore throat

• Minimal upper respiratory symptoms

Patients are highly infectious despite having few or no symptoms.

Phase II — Symptomatic Upper Respiratory/Systemic Phase

Timeframe: Day 5–11

Pathophysiology

• Viral spread to the conducting airways

• Activation of innate immune responses

• Cytokine and interferon release

• Mild epithelial inflammation

Clinical features

• Fever

• Chills

• Dry cough

• Headache

• Myalgia

• Sore throat

• Loss of smell

• Loss of taste

• Malaise

• Diarrhea

• Vomiting

Clinical symptoms are largely driven by immune activation rather than tissue destruction.

Risk indicators for progression

• Persistent fever lasting more than 5 days

• Rising inflammatory markers (e.g., CRP, ferritin)

• Advanced age

• Multiple comorbidities

Phase III — Early pulmonary phase

Timeframe: Day 11–14

Pathophysiology

• Viral invasion of alveolar pneumocytes

• Localized pulmonary inflammation

• Interstitial edema

• Impaired gas exchange

Clinical features

• Shortness of breath

• Tachypnea

• Reduced exercise tolerance

• Mild hypoxemia

Typical imaging findings

• Bilateral peripheral ground-glass opacities

• Patchy infiltrates

Patients may deteriorate rapidly within 24–48 hours during this transition from mild to severe disease.

Phase IV — Pulmonary

hyperinflammatory Phase

Timeframe: Day 14–28

Pathophysiology

• Dysregulated immune response ("cytokine storm")

• Diffuse alveolar damage

• Capillary leak syndrome

• Microvascular thrombosis

• Multi-organ injury

This phase commonly progresses to Acute Respiratory Distress Syndrome (ARDS).

Clinical features

• Severe hypoxemia

• Progressive dyspnea

• Cyanosis

• Respiratory failure

• Septic shock

• Multi-organ dysfunction

Potential complications

• Acute Respiratory Distress Syndrome (ARDS)

• Sepsis

• Septic shock

• Venous thromboembolism

• Pulmonary embolism

• Acute myocardial injury

• Heart failure

• Acute kidney injury

• Acute liver injury

• Disseminated intravascular coagulation (DIC)

Summary of Disease Timeline

Key clinical insight

COVID-19 is a time-dependent disease, and management strategies should be tailored to the stage of illness. Early recognition and intervention during the viral replication and early symptomatic phases can reduce progression to severe disease. As illness advances, management increasingly focuses on controlling excessive inflammation, preventing thromboembolic complications, supporting failing organs, and providing multidisciplinary rehabilitation. Continuous clinical reassessment remains essential because patients may deteriorate rapidly, particularly during the transition from the early pulmonary phase to the hyperinflammatory phase.